Skip to main content
Articles & Publications , Thierry Van Nieuwenhove

Translational Pharmaceutics® Platform Remains a Primary Goal for Quotient Sciences

In this article by 247 BioPharma, Thierry Van Nieuwenhove, the CEO of Quotient Sciences discusses the primary company goals and what steps the Quotient Sciences is taking to meet evolving regulatory requirements.

In addition, Thierry talks about the importance of partnerships and collaborations for the Quotient Sciences growth strategy and what key innovations, or new products will company be showcasing at CPHI Milan this year.

Continue reading the full article or watching the video on 247Bio Pharma.

Latest news from Quotient Sciences

More News
Articles & Publications, News & Announcements, Dr. Asma Patel Dr. Asma Patel contributes to PharmTech By: Dr. Asma Patel
Read More
Translational Pharmaceutics®, Articles & Publications, News & Announcements John McDermott Contributes to European Pharmaceutical Manufacturer By: John McDermott
Read More
Let's Talk
Your breakthrough therapy deserves momentum, and every day matters. Start a conversation with us today.